# Nippon Kayaku

Source: https://onco.cc/companies/nippon-kayaku/  
OnCo record `nippon-kayaku` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nippon Kayaku is a Japanese chemicals and pharmaceuticals group whose medicines business specialises in cancer: generic chemotherapy, supportive care products and biosimilars of antibodies such as trastuzumab for the Japanese market.

## Summary

Nippon Kayaku, listed in Tokyo, is a diversified chemicals company whose pharmaceutical division concentrates on oncology in Japan, supplying generic cytotoxic drugs, supportive care medicines and biosimilar antibodies including a trastuzumab biosimilar, and running the domestic phase 3 trials that biosimilar approval in Japan requires. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Nippon Kayaku Co., Ltd.; 日本化薬
- Tags: ctgov-sponsor
- HQ: Tokyo
- Type: pharma
- Website: https://www.nipponkayaku.co.jp/english/

## Sources

- Official website: https://www.nipponkayaku.co.jp/english/
- ClinicalTrials.gov: trials led by Nippon Kayaku: https://clinicaltrials.gov/search?lead=Nippon%20Kayaku
- Wikipedia: https://en.wikipedia.org/wiki/Nippon_Kayaku

## Connected records

- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/)

---
JSON: https://onco.cc/api/v1/entities/nippon-kayaku.json